Becton, Dickinson and Company $BDX Stock Holdings Trimmed by Trust Co. of Vermont

Trust Co. of Vermont lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 38,622 shares of the medical instruments supplier’s stock after selling 8,574 shares during the quarter. Trust Co. of Vermont’s holdings in Becton, Dickinson and Company were worth $7,495,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the period. United Bank lifted its stake in shares of Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Becton, Dickinson and Company by 9.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 15,402 shares of the medical instruments supplier’s stock valued at $2,653,000 after acquiring an additional 1,266 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in shares of Becton, Dickinson and Company by 183.4% during the second quarter. Loomis Sayles & Co. L P now owns 462 shares of the medical instruments supplier’s stock valued at $80,000 after acquiring an additional 299 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.4%

Shares of NYSE:BDX opened at $156.61 on Thursday. The stock has a market capitalization of $44.59 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 11.40 and a beta of 0.29. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a 50 day moving average price of $177.66 and a 200 day moving average price of $186.92.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the prior year, the company earned $3.43 earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its board has initiated a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BDX. TD Cowen upped their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Stifel Nicolaus lifted their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Argus dropped their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Barclays initiated coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective for the company. Finally, Jefferies Financial Group lowered their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $191.62.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,713 shares of company stock valued at $536,881. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.